US5726187A - N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists - Google Patents

N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists Download PDF

Info

Publication number
US5726187A
US5726187A US08/416,791 US41679195A US5726187A US 5726187 A US5726187 A US 5726187A US 41679195 A US41679195 A US 41679195A US 5726187 A US5726187 A US 5726187A
Authority
US
United States
Prior art keywords
alkyl
compound according
hydrogen
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/416,791
Inventor
Laramie Mary Gaster
Graham Francis Joiner
Keith Raymond Mulholland
Paul Adrian Wyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929221766A external-priority patent/GB9221766D0/en
Priority claimed from GB929223136A external-priority patent/GB9223136D0/en
Priority claimed from GB929223140A external-priority patent/GB9223140D0/en
Priority claimed from GB939305141A external-priority patent/GB9305141D0/en
Priority claimed from GB939309643A external-priority patent/GB9309643D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Assigned to SMITHKLINE BEECHAM P.L.C. reassignment SMITHKLINE BEECHAM P.L.C. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GASTER, LARAMIE MARY, JOINER, GRAHAM FRANCIS, MULHOLLAND, KEITH RAYMOND, WYMAN, PAUL ADRIAN
Application granted granted Critical
Publication of US5726187A publication Critical patent/US5726187A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to novel compounds having pharmacological activity, to a process for their preparation and to their use as pharmaceuticals.
  • EP-A-501322 (Glaxo Group Limited) describes indole derivatives having 5-HT 4 antagonist activity.
  • WO 93/02677 WO 93/03725, WO 93/05038, WO 93/05040 and WO 93/18036 (SmithKline Beecham plc) describe compounds having 5-HT 4 receptor antagonist activity.
  • ⁇ treatment ⁇ includes prophylaxis as appropriate.
  • the present invention provides compounds of formula (I), wherein formula (I) consists of formulae (I-1 ) to (I-5), and pharmaceutically acceptable salts thereof, and the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR2## wherein X and the carbon atoms to which it is attached represents phenyl, cyclohexyl or cyclohexenyl wherein X is --(CH 2 ) 4 --, and wherein X is optionally substituted by R 3 and R 4 ;
  • R 1 , R 2 , R 3 and R 4 are independently hydrogen, halo, C 1-6 alkyl, or C 1-6 alkoxy; ##STR3## wherein X is either --X 1 --(CH 2 ) x --X 2 -- in which X 1 --(CH 2 ) x --X 2 and the aromatic carbon atoms to which they are attached form a 5-7 membered ring wherein one of X 1 and X 2 is O, S or CH 2 and the other is CH 2 and x is 1, 2 or 3;
  • X is --X 3 --CH 2 --CH ⁇ CH--, --X 3- (CH 2 ) 2 --CO or --X 3 --(CH 2 ) 2 --CH(OR x )-- wherein X 3 is O or S and R x is hydrogen or C 1-6 alkyl;
  • R 1 is hydrogen, halo, C 1-6 alkyl, C 1-6 alkoxy or amino
  • R 2 and R 3 are hydrogen, halo, C 1-6 alkyl or C 1-6 alkoxy;
  • R 4 is hydrogen or C 1-6 alkyl and e is 1 or 2; ##STR4## wherein R 1 and R 2 are hydrogen, halo, C 1-6 alkyl or C 1-6 alkoxy; or
  • R 1 and R 2 are together either X 1 --(CH 2 ) x --X 2 in which X 1 --(CH 2 ) x --X 2 and the aromatic carbon atoms to which they are attached form a 5-7 membered ring wherein one of X 1 and X 2 is O, S or CH 2 and the other is CH 2 and x is 1, 2 or 3;
  • R 1 and R 2 are together X 3 --CH 2 --CH ⁇ CH--, X 3 --(CH 2 ) 2 --CO or X 3 --(CH 2 ) 2 --CH(OR x ) wherein X 2 is O or S and R x is hydrogen or C 1-6 alkyl;
  • R 1 /R 2 ring may be optionally substituted by one or two C 1-6 alkyl groups
  • R 3 is hydrogen, halo, C 1-6 alkyl, C 1-6 alkoxy or amino
  • R 4 is hydrogen, halo, C 1-6 alkyl or C 1-6 alkoxy and e is 1 or 2; ##STR5## wherein - - - represents a single or double bond;
  • R 1 is hydrogen, amino, halo, C 1-6 alkyl, hydroxy or C 1-6 alkoxy;
  • R 2 is hydrogen, halo, C 1-6 alkyl, C 1-6 alkoxy, nitro, amino or C 1-6 alkylthio;
  • R 3 is hydrogen, halo, C 1-6 alkyl, C 1-6 alkoxy or amino
  • R 4 is hydrogen or C 1-6 alkyl; ##STR6## wherein X is O or S;
  • R 1 is hydrogen, amino, halo, C 1-6 alkyl, hydroxy or C 1-6 alkoxy;
  • R 2 is hydrogen, halo, C 1-6 alkyl, C 1-6 alkoxy, nitro, amino or C 1-6 alkylthio;
  • R 3 is hydrogen, halo, C 1-6 alkyl, C 1-6 alkoxy or amino
  • R 4 is hydrogen or C 1-6 alkyl
  • Y is O or NH
  • Z is of sub-formula (a), (b) or (c): ##STR7## wherein n 1 is 0, 1, 2, 3 or 4; n 2 is 0, 1, 2, 3 or 4; n 3 is 2, 3, 4 or 5;
  • R 5 is hydrogen, C 1-12 alkyl, aralkyl or R 5 is (CH 2 ) z --R 10 wherein z is 2 or 3 and R 10 is selected from cyano, hydroxyl, C 1-6 alkoxy, phenoxy, C(O)C 1-6 alkyl, COC 6 H 5 , --CONR 11 R 12 , NR 11 COR 12 , SO 2 NR 11 R 12 or NR 11 SO 2 R 12 wherein R 11 and R 12 are hydrogen or C 1-6 alkyl; and
  • R 6 , R 7 and R 8 are independently hydrogen or C 1-6 alkyl
  • R 9 is hydrogen or C 1-10 alkyl
  • alkyl or alkyl containing groups include C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 or C 12 branched, straight chained or cyclic alkyl, as appropriate.
  • C 1-4 alkyl groups include methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl.
  • Cyclic alkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • Aryl includes phenyl and naphthyl optionally substituted by one or more substituents selected from halo, C 1-6 alkyl and C 1-6 alkoxy.
  • Halo includes fluoro, chloro, bromo and iodo.
  • X is often O and A represents a single bond.
  • R 1 is preferably methoxy.
  • R 2 is preferably hydrogen or halo.
  • R 3 is preferably hydrogen or halo.
  • R 4 is often hydrogen.
  • R 1 is preferably hydrogen or amino.
  • R 2 is preferably hydrogen or halo.
  • R 3 is preferably hydrogen or halo.
  • R 4 is often hydrogen.
  • R 1 is preferably hydrogen or amino.
  • R 2 is preferably hydrogen or halo.
  • R 3 is preferably hydrogen or halo.
  • R 4 is often hydrogen.
  • a suitable bioisostere for the amide or ester linkage containing Y in formula (I), is of formula (d): ##STR8## wherein the dotted circle represents one or two double bonds in any position in the 5-membered ring; H, J and I independently represent oxygen, sulphur, nitrogen or carbon, provided that at least one of H, J and I is other than carbon; U represents nitrogen or carbon.
  • Suitable examples of (d) are as described for X, Y and Z in EP-A-328200 (Merck Sharp & Dohme Ltd.), such as an oxadiazole moiety.
  • Y is preferably O or NH.
  • n 1 is preferably 2, 3 or 4 when the azacycle is attached at the nitrogen atom and n 1 is preferably 1 when the azacycle is attached at a carbon atom, such as the 4-position when q is 2.
  • n 2 is preferably such that the number of carbon atoms between the ester or amide linkage is from 2 to 4 carbon atoms.
  • n 3 is preferably 2, 3 or 4.
  • R 8 and R 9 are preferably both alkyl, especially one of R 8 and R 9 is C 4 or larger alkyl.
  • the invention also provides novel compounds within formula (I) with side chains (i), (ii), (iii), (iv), (v), (vi) or (vii).
  • the piperidine ring in (i), (ii) or (iii) may be replaced by pyrroiidinyl or azetidinyl, and/or the N-substituent in (i) or (ii) may be replaced by C 3 or larger alkyl or optionally substituted benzyl.
  • N-substituent in formula (i) or (ii) may be replaced by (CH 2 ) n R 4 as defined in formula (I) and in relation to the specific examples of EP-A-501322.
  • the pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts with conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids and pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, ⁇ -keto glutaric, ⁇ -glycerophosphoric, and glucose-1-phosphoric acids.
  • conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids
  • pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, ⁇ -keto glutaric, ⁇ -glycerophosphoric, and glucose-1-phosphoric acids.
  • Examples of pharmaceutically acceptable salts include quaternary derivatives of the compounds of formula (I) such as the compounds quaternised by compounds R x -T wherein R x is C 1-6 alkyl, phenyl-C 1-6 alkyl or C 5-7 cycloalkyl, and T is a radical corresponding to an anion of an acid.
  • R x include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl.
  • Suitable examples of T include halide such as chloride, bromide and iodide.
  • Examples of pharmaceutically acceptable salts also include internal salts such as N-oxides.
  • the compounds of formula (I) wherein CO--Y is an ester or amide linkage are prepared by conventional coupling of the Z moiety with the appropriate acid. Suitable methods are as described in GB 2125398A (Sandoz Limited), GB 1593146A, EP-A-36269, EP-A-289170 and WO 92/05174 (Beecham Group p.l.c.). When CO--Y is replaced by a heterocyclic bioisostere, suitable methods are described in EP-A-328200 (Merck Sharp & Dohme Limited). Reference is also made to EP-A-501322 (Glaxo Group Limited).
  • the invention also comprises a process for preparing the novel compounds of formula (I) which comprises reacting an appropriate acid derivative with an appropriate alcohol or amine.
  • a process comprises reacting an acid derivative wherein the aromatic substituents are as required in the end compound of formula (I), or substituents convertible thereto, with an alcohol or amine containing Z or a group convertible thereto, and thereafter if necessary, converting the benzoic acid substituents and/or Z, and optionally forming a pharmaceutically acceptable salt.
  • Suitable examples of conversions in the aromatic substituents include chlorination of hydrogen to chloro, reduction of nitro to amino, dehydrohalogenation such as debromination. Any elaboration is, however, usually carried out prior to ester or amide coupling.
  • Suitable examples of conversions in the Z containing moiety include conventional modifications of the N-substituent by substitution and/or deprotection or, in the case of a 2-, 3- or 4- substituted piperidinyl desired end compound, reduction of an appropriate pyridyl derivative.
  • the compounds of the present invention are 5-HT 4 receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and CNS disorders.
  • IBS irritable bowel syndrome
  • these compounds block the ability of 5-HT to stimulate gut motility via activation of enteric neurones. In animal models of IBS, this can be conveniently measured as a reduction of the rate of defaecation. They are also of potential use in the treatment of urinary incontinence which is often associated with IBS.
  • Anxiolytic activity is likely to be effected via the hippocampus (Dumuis et al 1988, Mol Pharmacol., 34, 880-887). Activity can be demonstrated in standard animal models, the social interaction test and the X-maze test.
  • Migraine sufferers often undergo situations of anxiety and emotional stress that precede the appearance of headache (Sachs, 1985, Migraine, Pan Books, London). It has also been observed that during and within 48 hours of a migraine attack, cyclic AMP levels are considerably increased in the cerebrospinal fluid (Welch et al., 1976, Headache 16, 160-167). It is believed that a migraine, including the prodomal phase and the associated increased levels of cyclic AMP are related to stimulation of 5-HT 4 receptors, and hence that administration of a 5-HT 4 antagonist is of potential benefit in relieving a migraine attack.
  • compositions are prepared by admixture and are usually adapted for enteral such as oral, nasal or rectal, or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, nasal sprays, suppositories, injectable and infusable solutions or suspensions.
  • enteral such as oral, nasal or rectal, or parenteral administration
  • enteral such as oral, nasal or rectal, or parenteral administration
  • enteral such as oral, nasal or rectal, or parenteral administration
  • enteral such as oral, nasal or rectal, or parenteral administration
  • enteral such as oral, nasal or rectal, or parenteral administration
  • enteral such as oral, nasal or rectal, or parenteral administration
  • enteral such as oral, nasal or rectal, or parenteral administration
  • oral liquid preparations powders, granules, lozenges, reconstitutable powders, nasal sprays, s
  • Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
  • the tablets may be coated according to well known methods in the art, for example with an enteric coating.
  • Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
  • Suitable disintegrants include starch, polyvinylpolypyrrolidone and starch derivatives such as sodium starch glycollate.
  • Suitable lubricants include, for example, magnesium stearate.
  • Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or
  • Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or colouring agents.
  • fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle.
  • the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
  • Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
  • a unit dose for a 70 kg adult will normally contain 0.05 to 1000 mg for example 0.5 to 500 mg, of the compound of the invention.
  • Unit doses may be administered once or more than once a day, for example, 2, 3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of approximately 0.0001 to 50 mg/kg/day, more usually 0.0002 to 25 mg/kg/day.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use in the treatment of irritable bowel syndrome, gastro-oesophageal reflux disease, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine.
  • N-Carboxy- 1-butylpiperidin-4-ylmethyl!-1,2,3,4,4a,9a-hexahydrocarbazole (0.530 g, 1.32 mmol) was dissolved in chloroform (25 ml) and treated with 2,3-dichloro-5,6-dicyano-1, 4-benzoquinone (0.329 g, 1.58 mmol) with stirring. The mixture was heated to reflux for 12 hours, cooled, and more 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (0.329 g 1.58 mmol) added with stirring. The mixture was heated to reflux for 12 hours, cooled and evaporated under reduced pressure.
  • Methyl-3-hydroxy-2-naphthoate (2.63 g, 0.013 mol) was dissolved in dry THF (80 ml) and treated with sodium hydride (80%) ((0.398 g, 0.013 mol), with stirring under N 2 .
  • sodium hydride 80%
  • propargyl bromide (80% in toluene) (2.57 ml 0.017 mol) was added and the mixture heated to reflux. After 20 h, the reaction mixture was allowed to cool and then evaporated under reduced pressure. The residue was then evaporated under reduced pressure. The residue was then partitioned between EtOAc and water.
  • Methyl-3-propargyloxy-2-naphthoate (D1 ) (1.00 g, 4.17 mmol) was dissolved in 1,2,dichlorobenzene (50 ml) and heated to reflux under N 2 with stirring. After 64 h, the reaction mixture was allowed to cool and was then evaporated under reduced pressure. The brown oily residue was then purified by silica-gel chromatography (Pentane: EtOAc 4:1 as eluant) to give the title compound to an orange oil (0.801 g, 80%).
  • Methyl-2H-3,4,dihydronaphtho 2.1-b!pyran-10-carboxylate (0.530 g, 2.19 mmol) was dissolved in ethanol (15 ml) and 10% NaOH (15 ml) was added. The mixture was then heated to reflux with stirring. After 6 h, the reaction mixture was allowed to cool and the ethanol present was removed by evaporation under reduced pressure. The aqueous residue was then acidified to pH 1 using conc. hydrochloric acid and the resultant oily suspension was extracted with CHCl 3 (3 ⁇ ). The combined organic layers were then dried (Na 2 SO 4 ) and evaporated under reduced pressure to give a pale yellow oil that crystallised on standing (0.499 g, 100%).
  • Indoline-7-carboxylic acid (Ger. Offen. 2,117,116) is coupled with lithium-(1-butyl-4-piperidinyl)methoxide via the imidazolide
  • 5-Chloro-2-methylbenzoxazole-7-carboxylic acid (Ger. Offen. 2,225,544) is converted to its acid chloride by treatment with oxalyl chloride.
  • the acid chloride is treated with N-(1-butyl-4-piperidinyl)methylamine in the presence of triethylamine to afford the title compound.
  • guinea-pigs Male guinea-pigs, weighing 250-400 g are used. Longitudinal muscle-myenteric plexus preparations, approximately 3 cm long, are obtained from the distal colon region. These are suspended under a 0.5 g load in isolated tissue baths containing Krebs solution bubbled with 5% CO 2 in O 2 and maintained at 37° C. In all experiments, the Krebs solution also contains methiothepin 10 -7 M and granisetron 10 -6 M to block effects at 5-HT 1 , 5-HT 2 and 5-HT 3 receptors.
  • a concentration of 5-HT is selected so as to obtain a contraction of the muscle approximately 40-70% maximum(10 -9 M approx).
  • the tissue is then alternately dosed every 15 min with this concentration of 5-HT and then with an approximately equi-effective concentration of the nicotine receptor stimulant, dimethylphenylpiperazinium (DMPP).
  • DMPP dimethylphenylpiperazinium
  • increasing concentrations of a putative 5-HT 4 receptor antagonist are then added to the bathing solution.
  • the effects of this compound are then determined as a percentage reduction of the contractions evoked by 5-HT or by DMPP. From this data, pIC 50 values are determined, being defined as the -log concentration of antagonist which reduces the contraction by 50%.
  • a compound which reduces the response to 5-HT but not to DMPP is believed to act as a 5-HT 4 receptor antagonist.
  • the compounds generally had a pIC 50 of at least 7.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Fused-ring system N-alkylpiperidinyl-4-methyl carboxylic acid ester or amide derivs. and analogues (D, having formula (I-1)-(I-5), and their salts. The variables are defined herein. The compounds (I) are 5-HT4 receptor antagonists, and are useful for treatment or prophylaxis of gastrointestinal, cardiovascular or CNS disorders. Typically (I) are used for treatment of irritable bowel syndrome (including associated diarrhea and urinary incontinence); for treatment of the nausea and gastric symptoms of gastro-oesophageal reflux disease and dyspepsia; as antiemetics (e.g. against cytotoxin agent or radiation-induced emesis); for preventing atrial fibrillation and other atrial arrhythmias and reducing occurrence of stroke; as anxiolytics; and for treatment of migraine, schizophrenia, Parkinson's disease and Huntington's chorea.

Description

This application is a 371 of PCT/GB93/02130, Oct. 14, 1993.
This invention relates to novel compounds having pharmacological activity, to a process for their preparation and to their use as pharmaceuticals.
European Journal of Pharmacology 146 (1988 ), 187-188, and Naunyn-Schmiedeberg's Arch. Pharmacol. (1989) 340:403-410, describe a non classical 5-hydroxytryptamine receptor, now designated the 5-HT4 receptor, and that ICS 205-930, which is also a 5-HT3 receptor antagonist, acts as an antagonist at this receptor. WO 91/16045 (SmithKline and French Laboratories Limited) describes the use of cardiac 5-HT4 receptor antagonists in the treatment of atrial arrhythmias and stroke.
EP-A-501322 (Glaxo Group Limited) describes indole derivatives having 5-HT4 antagonist activity.
WO 93/02677, WO 93/03725, WO 93/05038, WO 93/05040 and WO 93/18036 (SmithKline Beecham plc) describe compounds having 5-HT4 receptor antagonist activity.
It has now been discovered that certain novel compounds also have 5-HT4 receptor antagonist properties.
When used herein, `treatment` includes prophylaxis as appropriate.
Accordingly, the present invention provides compounds of formula (I), wherein formula (I) consists of formulae (I-1 ) to (I-5), and pharmaceutically acceptable salts thereof, and the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR2## wherein X and the carbon atoms to which it is attached represents phenyl, cyclohexyl or cyclohexenyl wherein X is --(CH2)4 --, and wherein X is optionally substituted by R3 and R4 ;
R1, R2, R3 and R4 are independently hydrogen, halo, C1-6 alkyl, or C1-6 alkoxy; ##STR3## wherein X is either --X1 --(CH2)x --X2 -- in which X1 --(CH2)x --X2 and the aromatic carbon atoms to which they are attached form a 5-7 membered ring wherein one of X1 and X2 is O, S or CH2 and the other is CH2 and x is 1, 2 or 3;
or X is --X3 --CH2 --CH═CH--, --X3- (CH2)2 --CO or --X3 --(CH2)2 --CH(ORx)-- wherein X3 is O or S and Rx is hydrogen or C1-6 alkyl;
R1 is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy or amino;
R2 and R3 are hydrogen, halo, C1-6 alkyl or C1-6 alkoxy;
R4 is hydrogen or C1-6 alkyl and e is 1 or 2; ##STR4## wherein R1 and R2 are hydrogen, halo, C1-6 alkyl or C1-6 alkoxy; or
R1 and R2 are together either X1 --(CH2)x --X2 in which X1 --(CH2)x --X2 and the aromatic carbon atoms to which they are attached form a 5-7 membered ring wherein one of X1 and X2 is O, S or CH2 and the other is CH2 and x is 1, 2 or 3;
or R1 and R2 are together X3 --CH2 --CH═CH--, X3 --(CH2)2 --CO or X3 --(CH2)2 --CH(ORx) wherein X2 is O or S and Rx is hydrogen or C1-6 alkyl;
and in which an R1 /R2 ring may be optionally substituted by one or two C1-6 alkyl groups;
R3 is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy or amino;
R4 is hydrogen, halo, C1-6 alkyl or C1-6 alkoxy and e is 1 or 2; ##STR5## wherein - - - represents a single or double bond;
R1 is hydrogen, amino, halo, C1-6 alkyl, hydroxy or C1-6 alkoxy;
R2 is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy, nitro, amino or C1-6 alkylthio;
R3 is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy or amino;
R4 is hydrogen or C1-6 alkyl; ##STR6## wherein X is O or S;
R1 is hydrogen, amino, halo, C1-6 alkyl, hydroxy or C1-6 alkoxy;
R2 is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy, nitro, amino or C1-6 alkylthio;
R3 is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy or amino;
R4 is hydrogen or C1-6 alkyl;
In formulae (I-1) to (I-5) inclusive:
Y is O or NH;
Z is of sub-formula (a), (b) or (c): ##STR7## wherein n1 is 0, 1, 2, 3 or 4; n2 is 0, 1, 2, 3 or 4; n3 is 2, 3, 4 or 5;
q is 0, 1, 2 or 3; p is 0, 1 or 2; m is 0, 1 or 2;
R5 is hydrogen, C1-12 alkyl, aralkyl or R5 is (CH2)z --R10 wherein z is 2 or 3 and R10 is selected from cyano, hydroxyl, C1-6 alkoxy, phenoxy, C(O)C1-6 alkyl, COC6 H5, --CONR11 R12, NR11 COR12, SO2 NR11 R12 or NR11 SO2 R12 wherein R11 and R12 are hydrogen or C1-6 alkyl; and
R6, R7 and R8 are independently hydrogen or C1-6 alkyl; and
R9 is hydrogen or C1-10 alkyl;
or a compound of formula (I) wherein the CO--Y linkage is replaced by a heterocyclic bioisostere;
in the manufacture of a medicament having 5-HT4 receptor antagonist activity.
Examples of alkyl or alkyl containing groups include C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11 or C12 branched, straight chained or cyclic alkyl, as appropriate. C1-4 alkyl groups include methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl. Cyclic alkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
Aryl includes phenyl and naphthyl optionally substituted by one or more substituents selected from halo, C1-6 alkyl and C1-6 alkoxy.
Halo includes fluoro, chloro, bromo and iodo.
In formula (I-2):
X is often O and A represents a single bond.
R1 is preferably methoxy.
R2 is preferably hydrogen or halo.
R3 is preferably hydrogen or halo.
R4 is often hydrogen.
In formula (I-4):
R1 is preferably hydrogen or amino.
R2 is preferably hydrogen or halo.
R3 is preferably hydrogen or halo.
R4 is often hydrogen.
In formula (I-5):
R1 is preferably hydrogen or amino.
R2 is preferably hydrogen or halo.
R3 is preferably hydrogen or halo.
R4 is often hydrogen.
A suitable bioisostere for the amide or ester linkage containing Y in formula (I), is of formula (d): ##STR8## wherein the dotted circle represents one or two double bonds in any position in the 5-membered ring; H, J and I independently represent oxygen, sulphur, nitrogen or carbon, provided that at least one of H, J and I is other than carbon; U represents nitrogen or carbon.
Suitable examples of (d) are as described for X, Y and Z in EP-A-328200 (Merck Sharp & Dohme Ltd.), such as an oxadiazole moiety.
Y is preferably O or NH.
When Z is of sub-formula (a), n1 is preferably 2, 3 or 4 when the azacycle is attached at the nitrogen atom and n1 is preferably 1 when the azacycle is attached at a carbon atom, such as the 4-position when q is 2.
When Z is of sub-formula (b), n2 is preferably such that the number of carbon atoms between the ester or amide linkage is from 2 to 4 carbon atoms.
Suitable values for p and m include p=m=1; p=0, m=1, p=1, m=2, p=2, m=1.
When Z is of sub-formula (c), n3 is preferably 2, 3 or 4.
R8 and R9 are preferably both alkyl, especially one of R8 and R9 is C4 or larger alkyl.
Specific values of Z of particular interest are as follows: ##STR9##
The invention also provides novel compounds within formula (I) with side chains (i), (ii), (iii), (iv), (v), (vi) or (vii). In a further aspect, the piperidine ring in (i), (ii) or (iii) may be replaced by pyrroiidinyl or azetidinyl, and/or the N-substituent in (i) or (ii) may be replaced by C3 or larger alkyl or optionally substituted benzyl.
In an alternative aspect, the N-substituent in formula (i) or (ii) may be replaced by (CH2)n R4 as defined in formula (I) and in relation to the specific examples of EP-A-501322.
The pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts with conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids and pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, α-keto glutaric, α-glycerophosphoric, and glucose-1-phosphoric acids.
Examples of pharmaceutically acceptable salts include quaternary derivatives of the compounds of formula (I) such as the compounds quaternised by compounds Rx -T wherein Rx is C1-6 alkyl, phenyl-C1-6 alkyl or C5-7 cycloalkyl, and T is a radical corresponding to an anion of an acid. Suitable examples of Rx include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl. Suitable examples of T include halide such as chloride, bromide and iodide.
Examples of pharmaceutically acceptable salts also include internal salts such as N-oxides.
The compounds of the formula (I), their pharmaceutically acceptable salts, (including quaternary derivatives and N-oxides) may also form pharmaceutically acceptable solvates, such as hydrates, which are included wherever a compound of formula (I) or a salt thereof is herein referred to.
The compounds of formula (I) wherein CO--Y is an ester or amide linkage are prepared by conventional coupling of the Z moiety with the appropriate acid. Suitable methods are as described in GB 2125398A (Sandoz Limited), GB 1593146A, EP-A-36269, EP-A-289170 and WO 92/05174 (Beecham Group p.l.c.). When CO--Y is replaced by a heterocyclic bioisostere, suitable methods are described in EP-A-328200 (Merck Sharp & Dohme Limited). Reference is also made to EP-A-501322 (Glaxo Group Limited).
The invention also comprises a process for preparing the novel compounds of formula (I) which comprises reacting an appropriate acid derivative with an appropriate alcohol or amine. A process comprises reacting an acid derivative wherein the aromatic substituents are as required in the end compound of formula (I), or substituents convertible thereto, with an alcohol or amine containing Z or a group convertible thereto, and thereafter if necessary, converting the benzoic acid substituents and/or Z, and optionally forming a pharmaceutically acceptable salt.
Suitable examples of conversions in the aromatic substituents include chlorination of hydrogen to chloro, reduction of nitro to amino, dehydrohalogenation such as debromination. Any elaboration is, however, usually carried out prior to ester or amide coupling.
Suitable examples of conversions in the Z containing moiety include conventional modifications of the N-substituent by substitution and/or deprotection or, in the case of a 2-, 3- or 4- substituted piperidinyl desired end compound, reduction of an appropriate pyridyl derivative.
The compounds of the present invention are 5-HT4 receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and CNS disorders.
They are of potential interest in the treatment of irritable bowel syndrome (IBS), in particular the diarrhoea aspects of IBS, i.e., these compounds block the ability of 5-HT to stimulate gut motility via activation of enteric neurones. In animal models of IBS, this can be conveniently measured as a reduction of the rate of defaecation. They are also of potential use in the treatment of urinary incontinence which is often associated with IBS.
They may also be of potential use in other gastrointestinal disorders, such as those associated with upper gut motility, and as antiemetics. In particular, they are of potential use in the treatment of the nausea and gastric symptoms of gastro-oesophageal reflux disease and dyspepsia. Antiemetic activity is determined in known animal models of cytotoxic-agent/radiation induced emesis.
Specific cardiac 5-HT4 receptor antagonists which prevent atrial fibrillation and other atrial arrhythmias associated with 5-HT, would also be expected to reduce occurrence of stroke (see A. J. Kaumann 1990, Naumyn-Schmiedeberg's Arch. Pharmacol. 342, 619-622, for appropriate animal test method).
Anxiolytic activity is likely to be effected via the hippocampus (Dumuis et al 1988, Mol Pharmacol., 34, 880-887). Activity can be demonstrated in standard animal models, the social interaction test and the X-maze test.
Migraine sufferers often undergo situations of anxiety and emotional stress that precede the appearance of headache (Sachs, 1985, Migraine, Pan Books, London). It has also been observed that during and within 48 hours of a migraine attack, cyclic AMP levels are considerably increased in the cerebrospinal fluid (Welch et al., 1976, Headache 16, 160-167). It is believed that a migraine, including the prodomal phase and the associated increased levels of cyclic AMP are related to stimulation of 5-HT4 receptors, and hence that administration of a 5-HT4 antagonist is of potential benefit in relieving a migraine attack.
Other CNS disorders of interest include schizophrenia, Parkinson's disease and Huntingdon's chorea.
The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Such compositions are prepared by admixture and are usually adapted for enteral such as oral, nasal or rectal, or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, nasal sprays, suppositories, injectable and infusable solutions or suspensions. Orally administrable compositions are preferred, since they are more convenient for general use.
Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art, for example with an enteric coating.
Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpolypyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate.
Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or colouring agents.
The oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.
Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
The invention further provides a method of treatment or prophylaxis of irritable bowel syndrome, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine in mammals, such as humans, which comprises the administration of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
An amount effective to treat the disorders hereinbefore described depends on the relative efficacies of the compounds of the invention, the nature and severity of the disorder being treated and the weight of the mammal. However, a unit dose for a 70 kg adult will normally contain 0.05 to 1000 mg for example 0.5 to 500 mg, of the compound of the invention. Unit doses may be administered once or more than once a day, for example, 2, 3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of approximately 0.0001 to 50 mg/kg/day, more usually 0.0002 to 25 mg/kg/day.
No adverse toxicological effects are indicated within the aforementioned dosage ranges.
The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use in the treatment of irritable bowel syndrome, gastro-oesophageal reflux disease, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine.
The following Examples illustrates the preparation of compounds of formula (I), and the following Descriptions relate to the preparation of intermediates. The compounds of formula (I-1) and intermediates are prepared in Examples and Descriptions 1-1, 2-1 etc, the compounds of formula (I-2) are prepared in Examples and Descriptions 1-2, 2-2 etc and similarly for the compounds of formulae (I-3) to (I-5).
It will be appreciated that any compound prepared wherein Y is O may be provided as the corresponding compound wherein Y is NH.
EXAMPLE (1-1) R1, R2, R3, R4, H, X is cyclohexyl, Y=O, Z=(i)! N-Carboxy- 1-butyl-4-piperidinylmethyl!-1,2,3,4,4a,9a-hexahydrocarbazole
1-Butyl-4-piperidinylmethanol (0.500 g 2.12 mmol) was dissolved in dry THF (3 ml) and treated with methyllithium (1.5M solution in diethyl ether) 2.16 ml, 2.33 mmol) with stirring under nitrogen. After 10 minutes, N-chlorocarbonyl-1,2,3,4,4a,9a-hexahydrocarbazole (0.630 g, 2.68 mmol) (Ref: WO 89/09217) in dry THF (5 ml) was added dropwise with stirring. After 48 hours, the reaction mixture was filtered and the filtrate evaporated under reduced pressure. The residue was purified by silica-gel chromatography, eluting with 2% MeOH/CHCl3 -3%MeOH/CHCl3 to give the title compound as a clear, colourless oil, which was converted to the oxalate salt, nap 187°-189° C.
1 H NMR (250 MHz, CDCl3) (free base)
δ:7.90-7.60 (s br, 1H) 7.25-7.10 (m, 2H), 7.00 (t. 1H), 4.45-4.30 (m br, 1H), 4.10 (d, 2H), 3.45 (t, 1H), 3.00 (d, 2H), 2.45-2.20 (m, 3H), 2.10-1.95 (m, 3H),1.85-1.70 (m, 4H), 1.65-1.40 (m, 6H), 1.40-1.10 (m, 6H), 0.90 (t, 3H).
EXAMPLES 2-1 AND 3-1 R1, R2, R3, R4,=H, X is cyclohexenyl/phenyl, X=O, Z=(i)! N-Carboxy- 1-butyl-4-piperidinylmethyl!-1,2,3,4-tetrahydrocarbazole N-Carboxy- 1-butyl-4-piperidinylmethyl!-carbazole
N-Carboxy- 1-butylpiperidin-4-ylmethyl!-1,2,3,4,4a,9a-hexahydrocarbazole (0.530 g, 1.32 mmol) was dissolved in chloroform (25 ml) and treated with 2,3-dichloro-5,6-dicyano-1, 4-benzoquinone (0.329 g, 1.58 mmol) with stirring. The mixture was heated to reflux for 12 hours, cooled, and more 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (0.329 g 1.58 mmol) added with stirring. The mixture was heated to reflux for 12 hours, cooled and evaporated under reduced pressure. The residue was purified by Silica-gel chromatography, eluting with 2%MeOH/CHCl3 to give the title compounds as 3:1 mixture. The mixture was separated by preparative HPLC using a Waters Micro Bondapak C18 (300 mm×7.8 mm) column and eluting with 75:25 MeCN: 0.1M Ammonium Acetate (pH 5.0).
(2-1) 1H NMR (400 MHz, CDCl3)
δ:8.10 (d, 1H), 7.40 (d, 1H), 7.28-7.18 (m. 2H), 4.28 (d, 2H), 3.03-2.95 (m,4H),2.68-2.62 (m, 2H), 2.35 (t, 2H), 2.00-1.80 (m, 5H), 1.53-1.38 (m, 4H), 1.35-1.25 (m, 3H), 0.92 (t, 3H).
(3-1) 1H NMR (400 MHz, CDCl3)
δ: 8.28 (d, 2H), 8.00 (d, 2H), 7.50 (t, 2H), 7.38 (t, 2H), 4.48 (d, 2H), 3.05-2.95 (m, 4H), 2.65-2.60 (m, 2H), 2.35 (t, 2H), 2.00-1.75 (m,5H), 1.40-1.30 (m, 3H), 0.95 (t, 3H).
EXAMPLE 1-2 R1, R2, R3, R4,=H, X=O--(CH2)3 --, Y=O, Z=(i)! 1-Butylpiperidin-4-ylmethyl-3,4-dihydro-2H-naphtho 2,1-b!pyran-10-carboxylate
3,4-Dihydro-2H-naphtho 2,1-b!pyran-10-carboxylic acid (0.510 g, 2.24 mmol) was dissolved in CH2 Cl2 (20 ml) and treated with oxalyl chloride (0.292 ml, 3.35 mmol), followed by a drop of dry DMF with stirring under N2. After 3 h, the reaction mixture was evaporated under reduced pressure and dried in vacuo to give the crude acid chloride. Meanwhile, a solution of 1-butylpiperidin-4-yl methanol (0.363 g, 2.12 mmol) in dry THF (10 nil) was treated with 1.5M methyllithium (1.12 ml, 2.12 mmol). After 0.25 h to this solution was added the crude acid chloride in dry THF (10 ml) with stirring under N2. After 40 h, the reaction mixture was evaporated under reduced pressure and the residue partitioned between EtOAc and water. The aqueous layer was then extracted with EtOAc (1×) and the combined organic layers were dried (Na2 SO4) and evaporated under reduced pressure to give a yellow oil which was purified by silica gel chromatography (EtOAc as eluant) to give the title compound as a pale yellow oil (0.180 g, 21%) which was converted to its hydrochloride salt m.p. (HCl salt) 137°-139° C.
1H NMR (CDCl3) 250 MHz (free base)
δ: 8.14(1H,s), 7.80(2H,m), 7.58(1H, t, J=7 Hz), 7.40(1H, t, J=7 Hz), 4.30(2H, t, J=6 Hz), 4.20(2H, d, J=6 Hz), 3.08(2H, t, J=6 Hz), 2.98(2H, d. J=12 Hz), 2.35(2H, t, J=6 Hz), 2.20(2H,m), 2.00-1.70(6H, m), 1.60-1.25(5H,m), 0.92(3H, t, J=6 Hz)
EXAMPLE 2-2 R1, R2, R3, R4,=H, X=O--CH2 --CH═CH--, Y=O, Z=(i)!, 1-Butylpiperidin-4-ylmethyl-2H-naphtho 2,1-b!pyran-10-carboxylate
This was prepared from 2H-naphtho 2,1-b!pyran-10-carboxylic acid using the method outlined in Example 1.
1 H NMR (CDCl3) 200 MHz
δ: 8.20(1H,s), 7.90(1H,d,J=8 Hz), 7.80(1H,d, J=8 Hz), 7.55(1H, t, J=8 Hz), 7.40(1H,t,J=8 Hz), 7.10(1H, d, J=12 Hz), 6.00 (1H, m), 4.92(2H, m), 4.20(2H, d, J=6 Hz), 3.00(2H, d, J=12 Hz), 2.35(2H, t, J=6 Hz), 2.05-1.75(5H,m), 1.60-1.32(6H, m), 0.95(3H, t, J=6 Hz).
DESCRIPTION 1-2 (Intermediate for Example 1-2) a) Methyl-3-propargyloxy-2-naphthoate
Methyl-3-hydroxy-2-naphthoate (2.63 g, 0.013 mol) was dissolved in dry THF (80 ml) and treated with sodium hydride (80%) ((0.398 g, 0.013 mol), with stirring under N2. After 0.5 h, propargyl bromide (80% in toluene) (2.57 ml 0.017 mol) was added and the mixture heated to reflux. After 20 h, the reaction mixture was allowed to cool and then evaporated under reduced pressure. The residue was then evaporated under reduced pressure. The residue was then partitioned between EtOAc and water. The aqueous layer was then extracted with EtOAc (1×), and the combined organic layers were dried (Na2 SO4) and evaporated to given an orange oil. Crystallisation of the oil from petrol (60/80) diethyl ether provided the title compound as a pale yellow solid (1.0 gg, 35%).
1 H NMR (CDCl3) 250 MHz
δ: 8.34(1H, s), 7.80(1H,dd, J=16 and 8 Hz), 7.53(1H, t, J=8 Hz), 7.40(1H, t,J=8 Hz), 4.90(2H, d,J=1 Hz), 3.95(3H, s), 2.57(1H, t, J=1 Hz)
b) Methyl-2H-naphtho 2,1-b!pyran-10-carboxylate
Methyl-3-propargyloxy-2-naphthoate (D1 ) (1.00 g, 4.17 mmol) was dissolved in 1,2,dichlorobenzene (50 ml) and heated to reflux under N2 with stirring. After 64 h, the reaction mixture was allowed to cool and was then evaporated under reduced pressure. The brown oily residue was then purified by silica-gel chromatography (Pentane: EtOAc 4:1 as eluant) to give the title compound to an orange oil (0.801 g, 80%).
'H NMR (CDCl3) 250 MHz
δ: 8.20(1H,s), 7.92(1H, d, J=8 Hz), 7.80(1H, d, J=8 Hz), 7.54 (1H, t, J=8 Hz), 7.40(1H,t,J=8 Hz), 7.12(1H, d,J=8 Hz), 6.00(1H,m), 4.94(2H,m), 3.94(3H,s)
c) Methyl-3,4-dihydro-2H-naphtho 2, 1-b!pyran-10-carboxylate
Methyl-2H-naphtho 2, 1-b!pyran-10-carboxylate (0.590 g, 2.46 mmol) was dissolved in ethyl acetate (30 ml) and 5% PdC (0.2 g) was added under N2. The mixture was then hydrogenated at atmospheric pressure. When theoretical H2 uptake had been achieved, the reaction mixture was flushed with N2 and then filtered through a pad of celite. The filtrate was then evaporated under reduced pressure and dried in vacuo to give the title compound as a pale yellow oil (0.154 g, 91%).
1 H NMR (CDCl3) 200 MHz
δ:8.20 (1H, s), 7.82 (1H, d, J=8 Hz), 7.58(1H, t, J=8 Hz), 7.40(1H, t, J=8 Hz), 4.37(2H, t, J=6 Hz), 3.98(3H, s), 3.12(2H, t, J=6 Hz), 2.25(2H,m).
d) 3,4-Dihydro-2H-naphtho 2.1-b!pyran-10-carboxylic acid
Methyl-2H-3,4,dihydronaphtho 2.1-b!pyran-10-carboxylate (0.530 g, 2.19 mmol) was dissolved in ethanol (15 ml) and 10% NaOH (15 ml) was added. The mixture was then heated to reflux with stirring. After 6 h, the reaction mixture was allowed to cool and the ethanol present was removed by evaporation under reduced pressure. The aqueous residue was then acidified to pH 1 using conc. hydrochloric acid and the resultant oily suspension was extracted with CHCl3 (3×). The combined organic layers were then dried (Na2 SO4) and evaporated under reduced pressure to give a pale yellow oil that crystallised on standing (0.499 g, 100%).
1 H NMR (CDCl3) 200 MHz
δ:12.0-10.5 br(1H,s), 8.60(1H,s), 7.87(1H, d, J=8 Hz), 7.78(1H, d, J=8 Hz), 7.58(1H, t, J=8 Hz), 7.38(1H, t, J=8 Hz) 4.44(2H, t, J=6 Hz), 3.12(2H, t, J=6 Hz), 2.25(2H,m).
DESCRIPTION 2-2 (Intermediate for Example 2-2) 2H-Naphtho 2,1-b!pyran-10-carboxylic acid
This was prepared from methyl-2H-naphtho 2, 1-b!pyran-10-carboxylate using the method outlined in Description 1-2d).
1 H NMR (CDCl3) 200 MHz
δ: 8.60(1H,s), 7.90(2H,m), 7.60(1H,t,J=8Hz), 7.40(1H, t, J=8 Hz), 7.15 (1H, d, J=12 Hz), 6.08 (1H, m), 5.05(2H,m)
EXAMPLE 1-3 R1, R2, R3, R4,=H, Y=O, Z=(i)! 1-Butylpiperidin-4-ylmethylnaphthalene-1-carboxylate
To a slurry of 1-naphthoic acid (500 mg) in dichloromethane (30 ml) was added oxalyl chloride (510 ml) and N,N' dimethylformamide (2 drops). The resulting mixture was stirred at room temperature for 1 hour. The solvent was concentrated in vacuo to afford crude acid chloride. Methyllithium (2.14 ml of 1.5M soln. in diethyl ether) was added dropwise to a solution of 1-butyl-4-hydroxymethylpiperidine (500 mg) in dry THF (10 ml) at 0° C. Stirring was continued at 0° C. for 10 minutes. A solution of crude acid chloride in THF (10 ml) was added to the reaction mixture and stirring continued at room temperature overnight. Water (2 ml) was added and the solvent concentrated under reduced pressure. The residue was partitioned between chloroform and water. The organic phase was dried (Na2 SO4), filtered and concentrated in vacuo. The residue was chromatographed on silica using chloroform and ethanol as eluant to afford pure ester (502 mg). Treatment with ethereal HCl gave the title compound as a solid.
1 H NMR250 MHz (CDCl3) Free base
δ: 8.92(d, 1H), 8.19(d,1H), 8.03(d,1H), 7.89(d,1H), 7.44-7.65(m,3H), 4.28(d,2H), 2.99(d,2H), 2.32(t,2H), 1.71-2.02(m,5H), 1.43-1.58(m,4H), 1.23-1.41(m,2H), 0.9(t,3H).
EXAMPLE 1-4 - - - is single bond, R1, R2, R3, R4 ═H, Y=O, Z=(i)! 7-(1-Butyl-4-piperidinylmethyl)-1H-2,3-dihydroindolecarboxylate
Indoline-7-carboxylic acid (Ger. Offen. 2,117,116) is coupled with lithium-(1-butyl-4-piperidinyl)methoxide via the imidazolide
The following compounds are prepared similarly, using the appropriate acid:
EXAMPLE 2-4 - - - is single bond, R1 =H, R2 =Cl, R3, R4 =H, Y=O, Z=(i)! 7-(1-Butyl-4-piperidinylmethyl)-5-chloro-1H-2,3-dihydroindolecarboxylate EXAMPLE 2-4 - - - is double bond, R1, R2, R3, R4 =H, Y=O, Z=(i)! 7-(1-Butyl-4-piperidinylmethyl)-1H-indolecarboxylate EXAMPLE 4-4 - - - is double bond, R1 =H, R2 =Cl , R3, R4 =H,Y=O, Z=(i)! 7-(1-Butyl-4-piperidinylmethyl)-5-chloro-1 H-indolecarboxylate DESCRIPTION 1-5 N-(1-Butyl-4-piperidinyl)methylamine
A stirred solution of isonipecotamide (70 g, 0.55 mole) and 1-bromobutane (58.8 ml, 0.55 mole) in ethanol (700 ml) was treated with anhydrous potassium carbonate (152 g, 1.10 mole) and heated under reflux for 3 h. The mixture was allowed to cool, then filtered and the filtrate concentrated under vacuum. The residual oil was dissolved in chloroform (400 ml) and washed with water (1×300 ml), then dried (Na2 SO4) and concentrated under vacuum to leave a yellow oil (77.5 g). This oil was mixed thoroughly with phosphorus pentoxide (75 g) and the mixture heated at 160°-180° C. under nitrogen for 2.5 h with gentle stirring. The reaction mixture was allowed to cool, then treated with water (500 ml). When the solid mass had dissolved, the solution was basified by addition of solid K2 CO3 and extracted with ethyl acetate (2×400 ml). The combined extracts were dried (Na2 SO4) and concentrated in vacuo to leave a brown oil (78 g). This was dissolved in dry ether (400 ml) and added dropwise over 30 minutes to a stirred suspension of lithium aluminium hydride (25 g, 0.66 mole) in ether (200 ml) at 0° C under nitrogen. When addition was complete, the mixture was allowed to warm up to room temperature and stir for 18 h. It was re-cooled to 0° C and treated cautiously with water (25 ml), 10% NaOH solution (25 ml) and water again (75 ml). The mixture was filtered through kieselguhr and the filtrate concentrated in vacuo to leave a brown oil, which was distilled under vacuum to afford the title compound as a colourless oil (66 g, 71%) bp 96°-99° C. at 3 mm Hg.
1 H NMR (CDCl3)
δ: 2.90-3.02(m,2H), 2.58(d,2H), 2.25-2.38(m,2H), 1.65-2.00(m,4H), 1.08-1.58(m,9H), 0.92(t,3H).
EXAMPLE 1-5 R1 =H, R2 =Cl, R3, R4,=H, Y=O, Z=(i)! N- (1-Butyl-4-piperidinyl)methyl!5-chloro-2-methylbenzoxazole-7-carboxamide
5-Chloro-2-methylbenzoxazole-7-carboxylic acid (Ger. Offen. 2,225,544) is converted to its acid chloride by treatment with oxalyl chloride. The acid chloride is treated with N-(1-butyl-4-piperidinyl)methylamine in the presence of triethylamine to afford the title compound.
5-HT4 RECEPTOR ANTAGONIST ACTIVITY 1) Guinea pig colon
Male guinea-pigs, weighing 250-400 g are used. Longitudinal muscle-myenteric plexus preparations, approximately 3 cm long, are obtained from the distal colon region. These are suspended under a 0.5 g load in isolated tissue baths containing Krebs solution bubbled with 5% CO2 in O2 and maintained at 37° C. In all experiments, the Krebs solution also contains methiothepin 10-7 M and granisetron 10-6 M to block effects at 5-HT1, 5-HT2 and 5-HT3 receptors.
After construction of a simple concentration-response curve with 5-HT, using 30s contact times and a 15 min dosing cycle, a concentration of 5-HT is selected so as to obtain a contraction of the muscle approximately 40-70% maximum(10-9 M approx). The tissue is then alternately dosed every 15 min with this concentration of 5-HT and then with an approximately equi-effective concentration of the nicotine receptor stimulant, dimethylphenylpiperazinium (DMPP). After obtaining consistent responses to both 5-HT and DMPP, increasing concentrations of a putative 5-HT4 receptor antagonist are then added to the bathing solution. The effects of this compound are then determined as a percentage reduction of the contractions evoked by 5-HT or by DMPP. From this data, pIC50 values are determined, being defined as the -log concentration of antagonist which reduces the contraction by 50%. A compound which reduces the response to 5-HT but not to DMPP is believed to act as a 5-HT4 receptor antagonist.
The compounds generally had a pIC50 of at least 7.

Claims (10)

We claim:
1. Compounds of formula (I-1) or a pharmaceutically acceptable salt thereof: ##STR10## wherein X and the carbon atoms to which it is attached represents phenyl, cyclohexyl or cyclohexenyl optionally substituted by R3 and R4 ;
R1, R2, R3 and R4 are independently hydrogen, halo, C1-6 alkyl, or C1-6 alkoxy;
wherein
Y is O or NH;
Z is of sub-formula (a) ##STR11## wherein n1 is 1 and the azacycle is attached at the 4-position;
q is 1;
R5 is hydrogen, C1-12 alkyl, aralkyl or R5 is (CH2)z --R10 wherein z is 2 or 3 and R10 is selected from cyano, hydroxyl, C1-6 alkoxy, phenoxy, C(O)C1-6 alkyl, COC6 H5, --CONR11 R12, NR11 COR12, SO2 NR11 R12 or NR11 SO2 R12 wherein R11 and R12 are hydrogen or C1-6 alkyl; and
R6 is hydrogen or C1-6 alkyl;
or a compound of formula (I-1) wherein the CO--Y linkage is replaced by a heterocyclic bioisostere.
2. A compound according to claim 1 wherein Z is N-substituted 4-piperidylmethyl.
3. A compound according to claim 2 wherein the N-substituent is C2 or greater alkyl, or optionally substituted benzyl.
4. N-Carboxy- 1-butyl-4-piperidinylmethyl!-1,2,3,4,4a,9a-hexahydrocarbazole, a compound which is N-carboxy- 1-butyl-4-piperidinylmethyl!-1,2,3,4-tetrahydrocarbazole, or N-carboxy- 1-butyl-4-piperidinylmethyl!-carbazole.
5. A compound according to claim 1 but wherein Y is NH.
6. A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier.
7. A method for treating irritable bowel syndrome (IBS) which comprises administering a compound according to claim 1.
8. A method for treating urinary incontinence which comprises administering a compound according to claim 1.
9. A method for treating atrial arrhythmia or stroke which comprises administering a compound according to claim 1.
10. A method of treating anxiety, migraine, schizophrenia, Parkinson's disease and Huntingdon's chorea, which comprises administering a compound according to claim 1.
US08/416,791 1992-10-16 1993-10-14 N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists Expired - Fee Related US5726187A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB929221766A GB9221766D0 (en) 1992-10-16 1992-10-16 Pharmaceuticals
GB9221766 1992-10-16
GB9223140 1992-11-05
GB9223136 1992-11-05
GB929223136A GB9223136D0 (en) 1992-11-05 1992-11-05 Pharmaceuticals
GB929223140A GB9223140D0 (en) 1992-11-05 1992-11-05 Pharmaceuticals
GB9305141 1993-03-12
GB939305141A GB9305141D0 (en) 1993-03-12 1993-03-12 Pharmaceuticals
GB9309643 1993-05-11
GB939309643A GB9309643D0 (en) 1993-05-11 1993-05-11 Pharmaceuticals
PCT/GB1993/002130 WO1994008965A1 (en) 1992-10-16 1993-10-14 N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists

Publications (1)

Publication Number Publication Date
US5726187A true US5726187A (en) 1998-03-10

Family

ID=27517148

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/416,791 Expired - Fee Related US5726187A (en) 1992-10-16 1993-10-14 N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists

Country Status (4)

Country Link
US (1) US5726187A (en)
EP (1) EP0664794A1 (en)
JP (1) JPH08502283A (en)
WO (1) WO1994008965A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028292A1 (en) * 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
WO1999064055A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht4 receptors
US6432986B2 (en) 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US20030031625A1 (en) * 1999-08-11 2003-02-13 Lin Henry C. Methods of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US20040180834A1 (en) * 1995-05-17 2004-09-16 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US20060094715A1 (en) * 2002-05-16 2006-05-04 Levy Finn O 5-Ht4 receptor antagonists for the treatment of heart failure
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
WO2011030349A1 (en) 2009-09-14 2011-03-17 Suven Life Sciences Limited L -dihydro-2-oxoquinoline compounds a 5-ht4 receptor ligands

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
WO1994008965A1 (en) * 1992-10-16 1994-04-28 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists
IT1275903B1 (en) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia ESTERS AND AMIDES OF 1,4-PIPERIDINE DISPLACED
GB9618967D0 (en) * 1996-09-11 1996-10-23 Smithkline Beecham Plc Pharmaceuticals

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049556A (en) * 1988-03-23 1991-09-17 Beecham Group P.L.C. Certain N-azabicyclo-2,3-dihydro-indole-1-carboxamides having anti-emetic properties, further found useful in treating headaches, neuralgia and anxiety
WO1991016045A2 (en) * 1990-04-26 1991-10-31 Smith Kline & French Laboratories Limited Use of 5-ht4 receptor antagonists in the treatment of arrythmias and stroke
EP0501322A1 (en) * 1991-02-25 1992-09-02 Glaxo Group Limited 3-Piperidinylmethylcarboxylate substituted indoles
WO1993002677A1 (en) * 1991-08-03 1993-02-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
WO1993003725A1 (en) * 1991-08-20 1993-03-04 Smithkline Beecham Plc 5-ht4 receptor antagonists
WO1993005040A1 (en) * 1991-09-12 1993-03-18 Smithkline Beecham Plc Azabicyclic compounds as 5-ht4 receptor antagonists
WO1993005038A1 (en) * 1991-09-12 1993-03-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
WO1993008187A1 (en) * 1991-10-24 1993-04-29 Smithkline Beecham Plc Imidazopyridines and indolizines as 5-ht4 antagonists
WO1993012785A1 (en) * 1991-12-21 1993-07-08 Smithkline Beecham Plc Use of 5-ht4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
WO1993014745A1 (en) * 1992-01-23 1993-08-05 Smithkline Beecham Plc Use of 5-ht4 receptor antagonists as medicaments for treating migraine
WO1993016072A1 (en) * 1992-02-06 1993-08-19 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists
WO1993018036A1 (en) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Condensed indole derivatives as 5ht4-receptor antagonists
WO1993018027A1 (en) * 1992-03-03 1993-09-16 Smithkline Beecham Plc Nitrogen containing heterocyclic compounds useful as pharmaceuticals
WO1993024117A2 (en) * 1992-05-23 1993-12-09 Smithkline Beecham Plc Medicaments for the treatment of anxiety
WO1994000113A2 (en) * 1992-06-27 1994-01-06 Smithkline Beecham Plc Medicaments containing 5-ht4 receptor antagonists
WO1994001095A2 (en) * 1992-07-03 1994-01-20 Smithkline Beecham Plc Medicaments for the treatment of visceral pain and migraine
WO1994005654A1 (en) * 1992-09-10 1994-03-17 Smithkline Beecham Plc Heteroaryl compounds used as pharmaceuticals
WO1994007859A1 (en) * 1992-09-29 1994-04-14 Smithkline Beecham Plc 5-ht4 antagonists
WO1994008965A1 (en) * 1992-10-16 1994-04-28 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists
WO1994008995A1 (en) * 1992-10-13 1994-04-28 Smithkline Beecham Plc Heterocyclic condensed benzoic acid derivatives as 5-ht4 receptor antagonists
WO1994008998A1 (en) * 1992-10-13 1994-04-28 Smithkline Beecham Plc Imidazopyridine derivatives as 5-ht4 receptor antagonists
WO1994008994A1 (en) * 1992-10-13 1994-04-28 Smithkline Beecham Plc Heterocyclic -esters or -amides used as 5-ht4 receptor antagonists
WO1994010174A1 (en) * 1992-11-05 1994-05-11 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
WO1994017071A1 (en) * 1993-01-28 1994-08-04 Smithkline Beecham Plc Tricyclic heterocyclic compounds as 5-ht4 receptor antagonists
WO1994019344A1 (en) * 1993-02-19 1994-09-01 Smithkline Beecham Plc Amide compounds with pharmacological activity
WO1994027987A1 (en) * 1993-05-22 1994-12-08 Smithkline Beecham Plc 5-ht4 receptor antagonists
WO1994029298A1 (en) * 1993-06-16 1994-12-22 Smithkline Beecham Plc 8-amino-7-chloro-1,4-benzodioxan-5-carboxylic acid, -1-butyl-4-piperidinyl ester as a 5-ht4-receptor antagonist
WO1995004737A1 (en) * 1993-08-05 1995-02-16 Smithkline Beecham Plc Condensed indole derivatives as 5-ht4-receptor antagonists

Patent Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049556A (en) * 1988-03-23 1991-09-17 Beecham Group P.L.C. Certain N-azabicyclo-2,3-dihydro-indole-1-carboxamides having anti-emetic properties, further found useful in treating headaches, neuralgia and anxiety
WO1991016045A2 (en) * 1990-04-26 1991-10-31 Smith Kline & French Laboratories Limited Use of 5-ht4 receptor antagonists in the treatment of arrythmias and stroke
EP0501322A1 (en) * 1991-02-25 1992-09-02 Glaxo Group Limited 3-Piperidinylmethylcarboxylate substituted indoles
WO1993002677A1 (en) * 1991-08-03 1993-02-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
WO1993003725A1 (en) * 1991-08-20 1993-03-04 Smithkline Beecham Plc 5-ht4 receptor antagonists
WO1993005038A1 (en) * 1991-09-12 1993-03-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
WO1993005040A1 (en) * 1991-09-12 1993-03-18 Smithkline Beecham Plc Azabicyclic compounds as 5-ht4 receptor antagonists
WO1993008187A1 (en) * 1991-10-24 1993-04-29 Smithkline Beecham Plc Imidazopyridines and indolizines as 5-ht4 antagonists
WO1993012785A1 (en) * 1991-12-21 1993-07-08 Smithkline Beecham Plc Use of 5-ht4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
WO1993014745A1 (en) * 1992-01-23 1993-08-05 Smithkline Beecham Plc Use of 5-ht4 receptor antagonists as medicaments for treating migraine
WO1993016072A1 (en) * 1992-02-06 1993-08-19 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists
WO1993018027A1 (en) * 1992-03-03 1993-09-16 Smithkline Beecham Plc Nitrogen containing heterocyclic compounds useful as pharmaceuticals
WO1993018036A1 (en) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Condensed indole derivatives as 5ht4-receptor antagonists
WO1993024117A2 (en) * 1992-05-23 1993-12-09 Smithkline Beecham Plc Medicaments for the treatment of anxiety
WO1994000113A2 (en) * 1992-06-27 1994-01-06 Smithkline Beecham Plc Medicaments containing 5-ht4 receptor antagonists
WO1994001095A2 (en) * 1992-07-03 1994-01-20 Smithkline Beecham Plc Medicaments for the treatment of visceral pain and migraine
WO1994005654A1 (en) * 1992-09-10 1994-03-17 Smithkline Beecham Plc Heteroaryl compounds used as pharmaceuticals
WO1994007859A1 (en) * 1992-09-29 1994-04-14 Smithkline Beecham Plc 5-ht4 antagonists
WO1994008994A1 (en) * 1992-10-13 1994-04-28 Smithkline Beecham Plc Heterocyclic -esters or -amides used as 5-ht4 receptor antagonists
WO1994008995A1 (en) * 1992-10-13 1994-04-28 Smithkline Beecham Plc Heterocyclic condensed benzoic acid derivatives as 5-ht4 receptor antagonists
WO1994008998A1 (en) * 1992-10-13 1994-04-28 Smithkline Beecham Plc Imidazopyridine derivatives as 5-ht4 receptor antagonists
WO1994008965A1 (en) * 1992-10-16 1994-04-28 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists
WO1994010174A1 (en) * 1992-11-05 1994-05-11 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
WO1994017071A1 (en) * 1993-01-28 1994-08-04 Smithkline Beecham Plc Tricyclic heterocyclic compounds as 5-ht4 receptor antagonists
WO1994019344A1 (en) * 1993-02-19 1994-09-01 Smithkline Beecham Plc Amide compounds with pharmacological activity
WO1994027987A1 (en) * 1993-05-22 1994-12-08 Smithkline Beecham Plc 5-ht4 receptor antagonists
WO1994029298A1 (en) * 1993-06-16 1994-12-22 Smithkline Beecham Plc 8-amino-7-chloro-1,4-benzodioxan-5-carboxylic acid, -1-butyl-4-piperidinyl ester as a 5-ht4-receptor antagonist
WO1995004737A1 (en) * 1993-08-05 1995-02-16 Smithkline Beecham Plc Condensed indole derivatives as 5-ht4-receptor antagonists

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Beilstein online data for RN 64057 972. *
Beilstein online data for RN 64057-972.
Cecil Textbook of Medicine, 19th ed., edited by Wyngaarden, J.B. et al, 1992, pp. 1093 4, 1106 7, 1655 61, 1872 8, 1972 5, 2191 5, 1027 032, 2213 21, 2260 and 127. *
Cecil Textbook of Medicine, 19th ed., edited by Wyngaarden, J.B. et al, 1992, pp. 1093-4, 1106-7, 1655-61, 1872-8, 1972-5, 2191-5, 1027-032, 2213-21, 2260 and 127.
Clarke et al., Trends in Pharmacological Sciences, 10(10), pp. 385 386 (1989). *
Clarke et al., Trends in Pharmacological Sciences, 10(10), pp. 385-386 (1989).
Clarke et al., Trends in Pharmacological Sciences, 13(4), pp. 141 145 (1992). *
Clarke et al., Trends in Pharmacological Sciences, 13(4), pp. 141-145 (1992).
Drug Actions: Basic Principles and Therapeutic Aspects, Mutschler, E. et al., CRC Press, 1995, pp. 105, 309 12, 173, 325 7, 331, 414, 163, 499, 151 and 142. *
Drug Actions: Basic Principles and Therapeutic Aspects, Mutschler, E. et al., CRC Press, 1995, pp. 105, 309-12, 173, 325-7, 331, 414, 163, 499, 151 and 142.
Dumuis et al., European J. Pharmacology, vol. 146, pp. 187 188 (1988). *
Dumuis et al., European J. Pharmacology, vol. 146, pp. 187-188 (1988).
Dumuis et al., Naunyn Schmiedeberg s Archives of Pharmacology, vol. 340, pp. 403 410 (1989). *
Dumuis et al., Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 340, pp. 403-410 (1989).

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20040180834A1 (en) * 1995-05-17 2004-09-16 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US20060193871A1 (en) * 1995-05-17 2006-08-31 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US7081239B2 (en) 1995-05-17 2006-07-25 Cedars-Sinai Medical Center Burns And Allen Research Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
WO1998028292A1 (en) * 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
US6432986B2 (en) 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
WO1999064055A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht4 receptors
US7452857B2 (en) 1999-08-11 2008-11-18 Cedars-Sinai Medical Center Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7935799B2 (en) 1999-08-11 2011-05-03 Cedars-Sinai Medical Center Methods of treating diarrhea caused by small intestinal bacterial overgrowth
US9358276B2 (en) 1999-08-11 2016-06-07 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7056686B2 (en) 1999-08-11 2006-06-06 Cedars-Sinai Medical Center Method of diagnosing fibromyalgia caused by small intestinal bacterial overgrowth
US20050008652A1 (en) * 1999-08-11 2005-01-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6805852B2 (en) 1999-08-11 2004-10-19 Cedars-Sinai Medical Center Methods of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US8562952B2 (en) 1999-08-11 2013-10-22 Cedars-Sinai Medical Center Methods for manipulating satiety
US20080014184A1 (en) * 1999-08-11 2008-01-17 Cedars-Sinai Medical Center Methods of treating fibromyalgia caused by small intestinal bacterial overgrowth
US20080014185A1 (en) * 1999-08-11 2008-01-17 Cedars-Sinai Medical Center Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US20090012113A1 (en) * 1999-08-11 2009-01-08 Cedars-Sinai Medical Center Methods of treating a subject suffering from irritable bowel syndrome
US8388935B2 (en) 1999-08-11 2013-03-05 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7585838B2 (en) 1999-08-11 2009-09-08 Cedars-Sinai Medical Center Methods of treating fibromyalgia caused by small intestinal bacterial overgrowth
US7605240B2 (en) 1999-08-11 2009-10-20 Cedara-Sinai Medical Center Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth
US8197805B2 (en) 1999-08-11 2012-06-12 Cedars-Sinai Medical Center Methods of treating autoimmune diseases caused by small intestinal bacterial overgrowth
US8110177B2 (en) 1999-08-11 2012-02-07 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20090325994A1 (en) * 1999-08-11 2009-12-31 Cedars-Sinai Medical Center Methods of treating diarrhea caused by small intestinal bacterial overgrowth
US7718608B2 (en) 1999-08-11 2010-05-18 Cedars-Sinai Medical Center Methods of treating a subject suffering from irritable bowel syndrome
US7736622B2 (en) 1999-08-11 2010-06-15 Cedars-Sinai Medical Center Methods of diagnosing small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20030031625A1 (en) * 1999-08-11 2003-02-13 Lin Henry C. Methods of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US20110171232A1 (en) * 1999-08-11 2011-07-14 Cedars-Sinai Medical Center Methods of treating autoimmune diseases caused by small intestinal bacterial overgrowth
US20060029550A1 (en) * 1999-08-11 2006-02-09 Cedars-Sinai Medical Center Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7615207B2 (en) 2000-04-10 2009-11-10 Cedars-Sinai Medical Center Methods for treating irritable bowel syndrome
US7608245B2 (en) 2000-04-10 2009-10-27 Cedars-Sinai Medical Center Methods for manipulating satiety
US7244412B2 (en) 2000-04-10 2007-07-17 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US20090169545A1 (en) * 2002-05-16 2009-07-02 Serodus As 5-ht4 receptor antagonists for the treatment of heart failure
US8829028B2 (en) 2002-05-16 2014-09-09 Serodus As 5-HT4 receptor antagonists for the treatment of heart failure
US20060094715A1 (en) * 2002-05-16 2006-05-04 Levy Finn O 5-Ht4 receptor antagonists for the treatment of heart failure
WO2011030349A1 (en) 2009-09-14 2011-03-17 Suven Life Sciences Limited L -dihydro-2-oxoquinoline compounds a 5-ht4 receptor ligands
US8598204B2 (en) 2009-09-14 2013-12-03 Suven Life Sciences Limited 1,2-dihydro-2-oxoquinoline compounds as 5-HT4 receptor ligands

Also Published As

Publication number Publication date
EP0664794A1 (en) 1995-08-02
WO1994008965A1 (en) 1994-04-28
JPH08502283A (en) 1996-03-12

Similar Documents

Publication Publication Date Title
US5705498A (en) Piperidine derivatives as 5-HT4 receptor antagonists
US5552398A (en) Azabicyclic compounds as 5-HT4 receptor antagonists
US6114329A (en) 5-HT4 receptor antagonists useful in the treatment of gastroinstestinal, cardiovascular and CNS disorders
NZ243993A (en) Pharmaceutical compositions having 5-ht4 receptor antagonist activity and selected compounds having such activity
US5696129A (en) 5-HT4 antagonists
US5726187A (en) N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists
EP0664806A1 (en) Heterocyclic condensed benzoic acid derivatives as 5-ht 4? receptor antagonists
US5708174A (en) Heterocyclic-esters or -amides used as 5-HT4 receptor antagonists
WO1994008998A1 (en) Imidazopyridine derivatives as 5-ht4 receptor antagonists
US5620992A (en) Heteroaryl compounds used as pharmaceuticals
AU3571893A (en) Indole or benzimidazole derivatives
US5705509A (en) Tricyclic heterocyclic compounds as 5-HT4 receptor antagonists
EP0712406B1 (en) Condensed indole derivatives as 5-ht 4-receptor antagonists
US6127379A (en) Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists
WO1994019344A1 (en) Amide compounds with pharmacological activity
US20040176370A1 (en) 3,4-Dihdro-N-[[1-(3-hydroxybutyl)-4-piperidinyl]methyl]-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide as 5-HT(4) receptor antagonist

Legal Events

Date Code Title Description
AS Assignment

Owner name: SMITHKLINE BEECHAM P.L.C., GREAT BRITAIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GASTER, LARAMIE MARY;JOINER, GRAHAM FRANCIS;MULHOLLAND, KEITH RAYMOND;AND OTHERS;REEL/FRAME:007463/0181

Effective date: 19950320

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20020310